1340 related articles for article (PubMed ID: 33003377)
1. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.
McGowan EM; Haddadi N; Nassif NT; Lin Y
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003377
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Infection: A Role for S1P/S1P Receptor Signaling in the Nervous System?
Meacci E; Garcia-Gil M; Pierucci F
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942748
[TBL] [Abstract][Full Text] [Related]
3. Battling COVID-19 Pandemic: Sphingosine-1-Phosphate Analogs as an Adjunctive Therapy?
Naz F; Arish M
Front Immunol; 2020; 11():1102. PubMed ID: 32670273
[TBL] [Abstract][Full Text] [Related]
4. Role of the SphK-S1P-S1PRs pathway in invasion of the nervous system by SARS-CoV-2 infection.
Pan Y; Gao F; Zhao S; Han J; Chen F
Clin Exp Pharmacol Physiol; 2021 May; 48(5):637-650. PubMed ID: 33565127
[TBL] [Abstract][Full Text] [Related]
5. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
[TBL] [Abstract][Full Text] [Related]
6. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
Front Immunol; 2020; 11():588724. PubMed ID: 33117402
[TBL] [Abstract][Full Text] [Related]
7. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.
Saul S; Einav S
ACS Infect Dis; 2020 Sep; 6(9):2304-2318. PubMed ID: 32687696
[TBL] [Abstract][Full Text] [Related]
8. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
Front Immunol; 2020; 11():1880. PubMed ID: 32973779
[TBL] [Abstract][Full Text] [Related]
9. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
[TBL] [Abstract][Full Text] [Related]
10. Understanding COVID-19: From Origin to Potential Therapeutics.
Moazzam M; Sajid MI; Shahid H; Butt J; Bashir I; Jamshaid M; Shirazi AN; Tiwari RK
Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32823901
[TBL] [Abstract][Full Text] [Related]
11. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
[TBL] [Abstract][Full Text] [Related]
12. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the
López-Iranzo FJ; López-Rodas AM; Franco L; López-Rodas G
Curr Pharm Des; 2020; 26(35):4515-4521. PubMed ID: 32787748
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms Underlying Potential Therapeutic Approaches for COVID-19.
Benani A; Ben Mkaddem S
Front Immunol; 2020; 11():1841. PubMed ID: 32793246
[TBL] [Abstract][Full Text] [Related]
14. Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human Respiratory Epithelium.
Milewska A; Kula-Pacurar A; Wadas J; Suder A; Szczepanski A; Dabrowska A; Owczarek K; Marcello A; Ochman M; Stacel T; Rajfur Z; Sanak M; Labaj P; Branicki W; Pyrc K
J Virol; 2020 Jul; 94(15):. PubMed ID: 32434888
[TBL] [Abstract][Full Text] [Related]
15. Management of epigenomic networks entailed in coronavirus infections and COVID-19.
El Baba R; Herbein G
Clin Epigenetics; 2020 Aug; 12(1):118. PubMed ID: 32758273
[TBL] [Abstract][Full Text] [Related]
16. COVID-19: a conundrum to decipher.
Deshmukh V; Tripathi SC; Pandey A; Deshmukh V; Vykoukal J; Patil A; Sontakke B
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5830-5841. PubMed ID: 32495923
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory Drugs in the Management of SARS-CoV-2.
Burrage DR; Koushesh S; Sofat N
Front Immunol; 2020; 11():1844. PubMed ID: 32903555
[TBL] [Abstract][Full Text] [Related]
18. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
19. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
[TBL] [Abstract][Full Text] [Related]
20. Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19.
Hassan STS
Viruses; 2020 Apr; 12(4):. PubMed ID: 32340120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
